Literature DB >> 8166932

Two immunodominant regions revealed by monoclonal antibodies on the main structural protein p24 of bovine leukemia virus.

O Orlik1, J Ban, E Gieciova, V Altanerova, C Altaner.   

Abstract

Eleven different monoclonal antibodies (Mabs) directed against the main structural protein p24 of bovine leukemia virus (BLV) were prepared. All Mabs reacted with p24 in Western blot and in radioimmunoprecipitation. Competition antibody binding assays with the prepared Mabs distinguished three independent groups of Mabs. Two immunodominant regions (IDRs) of p24 BLV were defined by these Mabs. The Mabs were induced preferentially against two immunodominant regions on the native form of p24 BLV (BLVp24 IDR-1 and BLVp24 IDR-2). Mab of the third group was directed against a different immunogenic epitope of p24 BLV. A model of the IDRs based on the differences in the fine epitope specificity of Mabs defining these immunodominant regions is proposed.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8166932     DOI: 10.1089/vim.1993.6.245

Source DB:  PubMed          Journal:  Viral Immunol        ISSN: 0882-8245            Impact factor:   2.257


  3 in total

1.  Progression to persistent lymphocytosis and tumor development in bovine leukemia virus (BLV)-infected cattle correlates with impaired proliferation of CD4+ T cells in response to gag- and env-encoded BLV proteins.

Authors:  O Orlik; G A Splitter
Journal:  J Virol       Date:  1996-11       Impact factor: 5.103

2.  Polyclonal bovine sera but not virus-neutralizing monoclonal antibodies block bovine leukemia virus (BLV) gp51 binding to recombinant BLV receptor BLVRcp1.

Authors:  O Orlik; J Ban; J Hlavaty; C Altaner; R Kettmann; D Portetelle; G A Splitter
Journal:  J Virol       Date:  1997-04       Impact factor: 5.103

3.  IgG subclass antibodies to human and bacterial HSP60 are not associated with disease activity and progression over time in axial spondyloarthritis.

Authors:  Thomas Gelsing Carlsen; Astrid Hjelholt; Anne Grethe Jurik; Berit Schiøttz-Christensen; Anna Zejden; Gunna Christiansen; Bent Deleuran; Svend Birkelund
Journal:  Arthritis Res Ther       Date:  2013       Impact factor: 5.156

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.